FIG 9/477989

5951983



--- QUAD STATS ---

FILE: #12:/23/CD2019 SAMPLE: 059

DATE: 9/24/92 GATE G1-R1

PARMETER : FL1-H\(LOG) FL2-H(LOG) QUAD LOCATION: 17.15 9

TOTAL= 5000 GATED = 1290

QUAD	EVENTS	% GATED	%TOTAL	X MEAN	Y MEAN
1UL	299	23.18	3.98	11.41	284.69
2UR	851	65.97	17.02	32.70	630.65
3LL	135	10.47	2.70	4.08	3.31
4LR	5	0.39	0.10	25.11	6.54



FIG. 2A



FIG. 2B

FIG. 3A

PBMC WITHOUT LO-CD2-a



FIG. 3B

PBMC WITH LO-CD2-a



FIG. 4



LEU 5b+ (CD2+)
WITHOUT mAb
WITH mAb

T4+ (CD4+)
WITHOUT mAb
WITH mAb

T8+ (CD8+)
WITHOUT mAb
WITH mAb

Effects of LO-CD2a on Resting Cells during MLC



FIG. 8A

FIG. 5B


WITH LEU-5b
GAM-FITC
LO-CD2-a-FITC
TII-RDI
PERCENTAGE POSITIVE CELLS
100
80
60
40
20
0
0
2
4
6
DAYS OF CULTURE

FIG. 5A


WITH LO-CD2-a
MARK-FITC
LEU-5b-FITC
TII-RDI
PERCENTAGE OF POSITIVE CELLS
100
80
60
40
20
0
0
2
4
6
DAYS OF CULTURE



FIG. 6B



FIG. 6D



FIG. 6A



FIG. 6C


MLC: LEU-5b+ (CD2+) CELLS
100
80
60
40
20
0
PERCENTAGE POSITIVE LYMPHOCYTES
WITHOUT LO-CD2-a
WITH LO-CD2-a
0
2
4
6
DAYS OF CULTURE

FIG. 8B

FIG. 7





Figure 9


Effects of LO-CD2-a on mitogen-stimulated PBMC
RPMI
Mitogen
Mitogen then LO-CD2-a
LO-CD2-a then Mitogen
LO-CD2-a
+ OKT3
+ Con-A
+ PHA
30
25
20
15
10
5
3 H-Thym. Incorporation (cpm) x10 3

08/477989



FIG. 11d


100
80
60
40
20
0
% SPECIFIC LYSIS
50/1
100/1
200/1
E / T RATIO
+0.1 µg/ml
+1 µg/ml
+5 µg/ml

FIG. 11b


PERCENTAGE INHIBITION
100
80
60
40
20
0
DONOR 1
DONOR 2
DAY 0
DAY 1
DAY 2
OKT3 PHA CON-A
MITOGENS ADDED AT DAY 0.

FIG. 10


LYMPHIOCYTE COUNTS
CELL COUNTS 10^3/m m^3
0
1
2
3
4
5
6
7
D0
D1
D2
D3
D4
D5
D6
D7
D8
D9
D10
D11
D13
D15
D17
D21
TIME (DAYS)
LOCD2 20mg/DAY
D0-D9

FIG. 12

FIG. 13

CELL POPULATIONS
LOCD2: 20 mg/DAY
DO-D9

FIG. 14


NK ACTIVITY
MONKEY #1992 AFTER LOCD2 10 DAYS
%LYSIS
40
30
20
10
0
0
25/1
50/1
100/1
E/T RATIO
DAY 22
DAY 11


LOCD2-a SERUM CONCENTRATION
CYNOMOLGUS MONKEY 1992
LOCD2-a μg/ml
50
40
30
20
10
0
D1
D2
D3
D4
D5
D6
D7
D8
D9
D10
DAYS

FIG. 15

FIG. 16



FIG. 17A



FIG. 17B



08/477989

FIG. 18A



FIG. 18B



08/477989

FIG. 19




CREATININE mg/dl OF BLOOD
5
4
3
2
1
TOTAL LEUCOCYTES
CRESTININE
LYMPHOCYTES
DAYS
29 27 25 23 21 19 17 15 13 11 9 7 5 3 1 0 -2 -4 -6 -8
LO-CD2-a
10
5
2
1
0,5
0,2
0,1
TOTAL LEUCOCYTES (X 10 / ml OF BLOOD
AND TYMPHOCYTES

FIG. 20

09/477989

FIG. 21



FIG. 22


CREATININ VALUES
PATIENT 2 AR.A.
LO-CD2-a 10 mg/d
CREAT mg/dl
5
4
3
2
1
0
10/24
10/25
10/26
10/27
10/28
10/29
10/30
10/31
11/01
11/02
11/03
11/04
11/05
11/06
11/07
11/08
11/09
11/10
11/11
11/12
DAYS
CREAT

FIG. 23


LEUCOCYTE COUNTS
PATIENT 2 AR.A.
LO-CD2-a 10mg/d
CELL COUNTS 10^6/ml
0
1
2
3
4
5
6
7
10/29
10/30
10/31
11/01
11/02
11/03
11/04
11/05
11/06
11/07
11/08
11/09
11/10
11/11
DAYS
TOTLEUCO
LYC



FIG. 24

FIG. 25


PATIENT 3 (D.D.)
LO-CD2-a 10 mg/d
CREATININ mg/dl
CELL COUNTS 10^6/ml
DAYS
TOTAL LEUOOCYTES
TOTAL LYMPHOCYTES
CREATININ LEVELS mg/dl

FIG. 26A

FIG. 26B

FIG. 26C

FIG. 26D

FIG. 26E

FIG. 26F

SINGLE STAINED CONTROLS

SINGLE STAINED CONTROLS

FIG. 26I

FIG. 26L

FIG. 26H

FIG. 26K

FIG. 26G

FIG. 26J

FIG. 27A



FIG. 27B



FIG. 27C



FIG. 27D



FIG. 27E



FIG. 27F



FIG. 27G



FIG. 27H



FIG. 27I



FIG. 27J



FIG. 27K



FIG. 27L



FIG. 28A



FIG. 28B



FIG. 28C



FIG. 28D



FIG. 28F



FIG. 28F



Lo-CD2a VL + Native Leader Sequence

Sequence Range: 1 to 761

```
        10        20        30        40        50        60        70        80        90       100
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
ATGATGAGTCCTGTCCAGTCCCTGTTTCTGTTATTGCTTTGGATTCTGGGTAAGTAGAGAATGAGTTACAGGACAAGAATGGGGATGGAGGATGAGTTCT
 M  M  S  P  V  Q  S  L  F  L  L  L  L  W  I  L  G>
-20

       110       120       130       140       150       160       170       180       190       200
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
GACTGCCCATGTTGGCTGTCCATGTGTGGTAAGGCAGGTCCTATTTTCTAAGATGGACACTTGAGATTCCATTACTTGATAATGAGAAATTACAGATGAG

       210       220       230       240       250       260       270       280       290       300
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
ATAGGATTTGTGCTAAGAGGATTCTAATGTAGATGAGAAGGTGTATGCCATTTAGGATCTGCAACCGAATTGTTTTGTGAAAAAGCATTTGGTATATTTT

       310       320       330       340       350       360       370       380       390       400
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
TTAAAAATCACAAAACACACCGGGATCTCACAGGAAATGAGTAACAAAAAGTAATTCACAAAGATTGGTTGCAAATTTTGCACATAACTTTGTTCTGATC

       410       420       430       440       450       460       470       480       490       500
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
TATTATAATTTCAGGAACCAATGGTGATGTTGTGCTGACCCAGACTCCACCTACTTTATTGGCTACCATTGGACAATCAGTCTCCATCTCTTGCAGGTCA
                  T  N  G  D  V  V  L  T  Q  T  P  P  T  L  L  A  T  I  G  Q  S  V  S  I  S  C  R  S>
                        1                    10                                   20

       510       520       530       540       550       560       570       580       590       600
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
AGTCAGAGTCTCTTACATAGTAGTGGAAACACCTATTTAAATTGGTTGCTACAGAGGACAGGCCAATCTCCACAGCCGCTAATTTATTTGGTATCCAAAC
 S  Q  S  L  L  H  S  S  G  N  T  Y  L  N  W  L  L  Q  R  T  G  Q  S  P  Q  P  L  I  Y  L  V  S  K>
          30                                   40                                   50

       610       620       630       640       650       660       670       680       690       700
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
TGGAATCTGGGGTCCCCAACAGGTTCAGTGGCAGTGGGTCAGGAACAGATTTCACACTCAAAATCAGTGGAGTGGAAGCTGAGGATTTGGGGGTTTATTA
L  E  S  G  V  P  N  R  F  S  G  S  G  S  G  T  D  F  T  L  K  I  S  G  V  E  A  E  D  L  G  V  Y  Y>
60                                   70                                   80                                   90

       710       720       730       740       750       760
    *   *   *   *   *   *   *   *   *   *   *   *
CTGCATGCAATTTACCCATTATCCGTACACGTTTGGAGCTGGGACCAAGCTGGAACTGAAA
  C  M  Q  F  T  H  Y  P  Y  T  F  G  A  G  T  K  L  E  L  K>
                  100                                  110
```

Fig-29

LoCD2a VH + Native Leader Sequence

Sequence Range: 1 to 491

```
      10        20        30        40        50        60        70        80        90       100
      *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
ATGAAATGCAGGTGGATCATCCTCTTCTTGATGGCAGTAGCTACAGGTAAGGCACTCCCAAGTCCTAAACTTGAGAGATCATACACTTGGGAGACAGTGA
  M  K  C  R  W  I  I  L  F  L  M  A  V  A  T  G>
-19

     110       120       130       140       150       160       170       180       190       200
      *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
CACTATCTTTGGATTTCTTTCAACAGGGGTCAACTCAGAAGTCCAGCTGCAGCAATCTGGGCCTGAGCTTCAGAGACCCGGGGCCTCAGTCAAGTTGTCG
                          V  N  S  E  V  Q  L  Q  Q  S  G  P  E  L  Q  R  P  G  A  S  V  K  L  S>
                                   1                          10                          20

     210       220       230       240       250       260       270       280       290       300
      *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
TGCAAGGCTTCTGGCTATATATTTACAGAATACTATATGTACTGGGTGAAGCAGAGGCCTAAACAGGGCCTGGAATTAGTAGGAAGGATCGATCCTGAAG
  C  K  A  S  G  Y  I  F  T  E  Y  Y  M  Y  W  V  K  Q  R  P  K  Q  G  L  E  L  V  G  R  I  D  P  E>
                          30                          40                          50

     310       320       330       340       350       360       370       380       390       400
      *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
ACGGTAGTATTGATTATGTTGAGAAGTTCAAAAAGAAGGCCACACTGACTGCAGATACATCGTCCAACACAGCCTACATGCAACTCAGCAGCCTGACATC
  D  G  S  I  D  Y  V  E  K  F  K  K  K  A  T  L  T  A  D  T  S  S  N  T  A  Y  M  Q  L  S  S  L  T  S>
                60                          70                          80

     410       420       430       440       450       460       470       480       490
      *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
TGAGGACACAGCAACCTATTTTTGTGCTAGGGGAAAATTCAACTATCGATTTGCTTACTGGGGCCAAGGCACCCTCGTCACAGTCTCCTCA
  E  D  T  A  T  Y  F  C  A  R  G  K  F  N  Y  R  F  A  Y  W  G  Q  G  T  L  V  T  V  S  S>
  90                          100                         110
```

Figure 30

5/17/95

Light Chain Variable Region Sequences of rat LO-CD2a, human HUM5400, and humanized LO-CD2a

```
                          FR 1                        CDR 1             FR 2
                             *    *      20        ___30 _______40 **         *
Rat LO-CD2a Vk      DVVLTQTPPT LLATIGQSVS ISCRSSQSLL HSSGNTYLNW LLQRTGQSPQ
Humanized Vk        ---M--S--S --V-L--PA- ---------- ---------- ----P-----
Human HUM5400 Vk    ---M--S-LS -PV-L--PA- ---------V Y-D---H--- FQ--P----R

                           CDR 2                  FR 3                 CDR 3
                    *   ___60 _      70         80 *        90    ____100
Rat LO-CD2a Vk      PLIYLVSKLE SGVPNRFSGS GSGTDFTLKI SGVEAEDLGV YYCMQFTHYP
Humanized Vk        ---------- ----D----- ---------- -------V-- ----------
Human HUM5400 Vk    R---K--NRD ----D----- ---------- -R-----V-- -----G--W-

                           FR 4
                    __     110
Rat LO-CD2a Vk      YTFGAGTKLE LK
Humanized Vk        ----Q----- I-
Human HUM5400 Vk    ----Q----- I-
```

31

Humanized LO-CD2a Light Chain V Region

Sequence Range: 1 to 807

```
      10        20        30        40        50        60        70        80        90       100
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
AAGCTTCATGATGAGTCCTGTCCAGTCCCTGTTTCTGTTATTGCTTTGGATTCTGGGTAAGTAGAGAATGAGTTACAGGACAAGAATGGGGATGGAGGAT
      M  M  S  P  V  Q  S  L  F  L  L  L  L  W  I  L  G>

     110       120       130       140       150       160       170       180       190       200
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
GAGTTCTGACTGCCCATGTTGGCTGTCCATGTGTGGTAAGGCAGGTCCTATTTTCTAAGATGGACACTTGAGATTCCATTACTTGATAATGAGAAATTAC

     210       220       230       240       250       260       270       280       290       300
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
AGATGAGATAGGATTTGTGCTAAGAGGATTCTAATGTAGATGAGAAGGTGTATGCCATTTAGGATCTGCAACCGAATTGTTTTGTGAAAAAGCATTTGGT

     310       320       330       340       350       360       370       380       390       400
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
ATATTTTTTAAAAATCACAAAACACACCGGGATCTCACAGGAAATGAGTAACAAAAAGTAATTCACAAAGATTGGTTGCAAATTTTGCACATAACTTTGT

     410       420       430       440       450       460       470       480       490       500
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
TCTGATCTATTATAATTTCAGGAACCAATGGTGATGTTGTGATGACCCAGAGTCCACCTTCATTATTGGTAACCTTGGGACAACCAGCTTCCATCTCTTG
                        T  N  G  D  V  V  M  T  Q  S  P  P  S  L  L  V  T  L  G  Q  P  A  S  I  S  C>

     510       520       530       540       550       560       570       580       590       600
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
CAGGTCAAGTCAGAGTCTCTTACATAGTAGTGGAAACACCTATTTAAATTGGTTGCTACAGAGGCCAGGCCAATCTCCACAGCCGCTAATTTATTTGGTA
  R  S  S  Q  S  L  L  H  S  S  G  N  T  Y  L  N  W  L  L  Q  R  P  G  Q  S  P  Q  P  L  I  Y  L  V>

     610       620       630       640       650       660       670       680       690       700
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
TCCAAACTGGAATCTGGGGTCCCCGACAGGTTCAGTGGCTCAGGGAGTGGAACAGATTTCACACTCAAAATCAGTGGAGTGGAAGCTGAGGATGTGGGGG
 S  K  L  E  S  G  V  P  D  R  F  S  G  S  G  S  G  T  D  F  T  L  K  I  S  G  V  E  A  E  D  V  G>

     710       720       730       740       750       760       770       780       790       800
   *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *    *
TTTATTACTGCATGCAATTTACCCATTATCCGTACACGTTTGGACAAGGGACCAAGCTGGAAATCAAACGTGAGTAGAATTTAAACTTTGCTTCCTCAGT
V  Y  Y  C  M  Q  F  T  H  Y  P  Y  T  F  G  Q  G  T  K  L  E  I  K>

   *
TGGATCC
```

Fig 32

5/17/95

09/477989

09/477989

Heavy Chain Variable Region Sequences of rat LO-CD2a, human Amu 5-3, and humanized LO-CD2a

```
                                       FR 1                     CDR 1      FR 2
                              10         20         30   _____     40         * 50
Rat LO-CD2a Vh        EVQLQQSGPE LQRPGASVKL SCKASGYIFT EYYMYWVKQR PKQGLELVGR
Humanized Vh          Q---V---A- VKK------V -------T-- -------R-A -G-----M--
Human Amu 5-3 Vh      Q---V---A- VKK------V -------T-- G---H--R-A -G----WM--

                         CDR 2                         FR 3
                      _________60 _______*  *   *    *  80      * * 90         100
Rat LO-CD2a Vh        IDPEDGSIDY VEKFKKKATL TADTSSNTAY MQLSSLTSED TATYFCARGK
Humanized Vh          ---------- -------V-- ------S--- -E------D- --V-Y-----
Human Amu 5-3 Vh      -N-NS-GTN- AQ--QGRV-M -R---IS--- -E--R-R-D- --V-Y----R

                        CDR 3         FR 4
                      ____________110
Rat LO-CD2a Vh        FNYR/////FAYWGQ GTLVTVSS
Humanized Vh          ----/////------ --------
Human Amu 5-3 Vh      TE-IVVAEG-D---- --------
```

Fig. 33

Humanized LO-CD2a Heavy chain V region

Sequence Range: 1 to 701

```
        10        20        30        40        50        60        70        80        90       100
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
AAGCTTCATGAAATGCAGGTGGATCATCCTCTTCTTGATGGCAGTAGCTACAGGTAAGGCACTCCCAAGTCCTAAACTTGAGAGATCATACACTTGGGAG
       M  K  C  R  W  I  I  L  F  L  M  A  V  A  T  G>

       110       120       130       140       150       160       170       180       190       200
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
ACAGTGACACTATCTTTGGATTTCTTTCAACAGGGGTCAACTCACAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAA
                                      V  N  S  Q  V  Q  L  V  Q  S  G  A  E  V  K  K  P  G  A  S  V  K>
                                                  I

       210       220       230       240       250       260       270       280       290       300
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
GGTCTCCTGCAAGGCTTCTGGATACACCTTCACCGAGTACTATATGTACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGCTGATGGGAAGGATCGAT
  V  S  C  K  A  S  G  Y  T  F  T  E  Y  Y  M  Y  W  V  R  Q  A  P  G  Q  G  L  E  L  M  G  R  I  D>

       310       320       330       340       350       360       370       380       390       400
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
CCTGAAGACGGTAGTATTGATTATGTTGAGAAGTTTAAGAAAAAGGTCACCCTGACCGCTGACACGTCCTCTAGCACAGCCTACATGGAGCTGAGCAGCC
 P  E  D  G  S  I  D  Y  V  E  K  F  K  K  K  V  T  L  T  A  D  T  S  S  S  T  A  Y  M  E  L  S  S>

       410       420       430       440       450       460       470       480       490       500
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
TGACCTCTGACGACACGGCCGTGTATTACTGTGCGAGAGGAAAGTTTAACTATAGGTTTGCTTACTGGGGCCAAGGAACCCTGGTCACCGTCTCCTCAGG
L  T  S  D  D  T  A  V  Y  Y  C  A  R  G  K  F  N  Y  R  F  A  Y  W  G  Q  G  T  L  V  T  V  S  S>

       510       520       530       540       550       560       570       580       590       600
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
TGAGTCCTTACAACCTCTCTCTTCTATTCAGCTTAAATAGATTTTACTGCATTTGTTGGGGGGGAAATGTGTGTATCTGAATTTCAGGTCATGAAGGACT

       610       620       630       640       650       660       670       680       690       700
    *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *   *
AGGGACACCTTGGGAGTCAGAAAGGGTCATTGGGAGCCCGGGCTGATGCAGACAGACATCCTCAGCTCCCGGACTTCATGGCCAGAGATTTATAGGGATC

C
```

Fig. 34

Binding of LO-CD2a and LO-CD2a Hu to Jurkat Cells



Fig. 35

Induction of Hyporesponsiveness *in vitro*



Fig. 36

A.


70000
60000
50000
40000
30000
20000
10000
0
CPM
2
3
4
5
6
7
8
DAY
Control
LO-CD2a

Fig. 37A


B.
Δ - LO-CD2a
∇ - control to Autologous stimulator cells
70000
60000
50000
40000
30000
20000
10000
0
CPM
2
3
4
5
6
7
8
DAY
Control Ab

1 of 3 B


C.
□ - LO-CD2a
Δ - Control Ab
(Primary MLR)
▽ - LO-CD2a
(Primary MLR)
Control Ab
CPM
70000
60000
50000
40000
30000
20000
10000
0
2
3
4
5
6
7
8
DAY

Fig. 37C


A.
30000
20000
10000
0
CPM
2
3
4
5
6
7
8
DAY
Control
LO-CD2a (with stimulator cells)
LO-CD2a
Control Ab (with stimulator cells)

Fig. 3A


B.
10000
8000
6000
4000
2000
0
CPM
2
3
4
5
6
7
8
DAY
Control Ab
LO-CD2a
No Ab, autologous stimulator cells

Fig. 38B


Percent of Control Response
150
100
50
0
0
500
1000
1500
2000
F(ab')2 of LG-CD2a Added (ng/ml)
Donor 2
Donor 3
Donor 4
Donor 1

Fig 39


Percent of Control Response
140
120
100
80
60
40
20
0
10^0
10^1
10^2
10^3
Antibody added (ng/ml)
F(ab')2 fragment
Intact Ab

Fig. 40


PBMC depleted of APC
Percent of Control Response
100
80
60
40
20
0
0
50
100
150
200
BTI-322 Added (ng/ml)
PBMC

Fig 41